Evolus, Inc. Common Stock
EOLSStock
$5.63−35.71%52W
Market Cap$399.74M
P/E—
Div yield—
Beta1.38
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-4.16%
Price vs S&P 500 (4W)-10.70%
VGM Score54.40
Market Capitalization$399.74M
Earnings Surprise History
Q1 26-0.05est. -0.13
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.23
4.23
4.23
4.23
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EOLSEvolus, Inc. Common Stock | C | B | C | $5.63 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Evolus Inc commercializes Jeuveau, a purified botulinum toxin formulation used to treat moderate to severe frown lines. The company generates revenue from product sales in the United States and Europe, and from distribution partnerships in Canada. Evolus operates in the self-pay aesthetic market, targeting physicians and consumers seeking non-invasive cosmetic treatments.